| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Tivic Health Systems (NASDAQ:TIVC) reported quarterly losses of $(2.00) per share. This is a 49.11 percent increase over losses...
New Biologics Patent Application Covers Potential Applicability of TLR5 Agonists to Improve Outcomes for Late-stage Cancer Ther...
https://patentcenter.uspto.gov/applications/18343848/ifw/docs
Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that it has completed veri...
INDs Transferred from Statera Biopharma Advance Entolimod for ARS Along Regulatory Pathway and Enable Pursuit of Clinical Trial...